drugset / Trial / NCT03244423
Tranexamic Acid in Cyanotic Heart Defects
RandomizedParallel-groupTriple-blindPrevention
Summary
The use of antifibrinolytic agents such as to reduce blood loss in congenital cardiac surgery has been described in many studies
Timeline
- Start
- 2009-01
- Primary completion
- 2017-08
- Completion
- 2017-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tranexamic Acid | Small molecule | 1 mg/kg | Intravenous |
| Comparator | Tranexamic Acid | Small molecule | 50 mg/kg | Intravenous |
Indications
No indication recorded.